S&P Futures
3,988.75 +18.25 (+0.46%) Dow Futures
32,400.00 +142.00 (+0.44%) Nasdaq Futures
12,768.50 +61.50 (+0.48%) Russell 2000 Futures
1,755.50 +14.50 (+0.83%) Crude Oil
70.15 -0.75 (-1.06%) Gold
1,978.30 +28.70 (+1.47%)
SBI Infrastructure Fund Direct Dividend Payout (0P0000XVJH.BO)
- Business Wire
Incyte Announces European Commission Approval of Jakavi® (ruxolitinib) as the First Post-Steroid Treatment for Acute and Chronic Graft-Versus-Host Disease
WILMINGTON, Del., May 05, 2022--Incyte Announces European Commission Approval of Jakavi (ruxolitinib) as the First Post-Steroid Treatment for Acute and Chronic GVHD.
- Business Wire
Incyte to Present at Upcoming Investor Conference
WILMINGTON, Del., May 04, 2022--Incyte (Nasdaq:INCY) announced today that it will present at the 2022 RBC Capital Markets Healthcare Conference on Tuesday, May 17, 2022 at 10:30 a.m. ET in New York.
- Benzinga
Despite Q1 Earnings Miss, Incyte Shares Jump On Revised FY22 Sales Guidance
View more earnings on INCYSee more from BenzingaThe Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme LayoffsGlobal Cord Blood Enters Therapy Market Via Cellenkos Acquisition For Over $600MDon't miss real-time alerts on your stocks - joinBenzinga Profor free! Try the tool that will help you invest smarter, faster, and better.© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
